Further studies are needed to disentangle the specific contributions of AD and DLB pathologies to metabolic dysfunction and cognitive decline, potentially through the use of additional imaging modalities such as neuroinflammation,45 tau PET,49, 50, 51 advanced MRI techniques such as Neurite Orientation Dispersion and Density Imaging (NODDI),52, 53, 54 and other markers of synaptic density using [11C]‐UCBJ‐J PET.55 The gene discussed is MAPT; the disease is Alzheimer disease.